TP-7, Thr-Lys-Pro-Arg-Pro-Gly-Pro
A seven-amino-acid peptide built from the immune peptide tuftsin plus a stabilizing Pro-Gly-Pro tail.
Category 2 is FDA’s list of bulk substances that may present significant safety risks in compounding. The 503A bulks list adds substances that pharmacies may compound with. Advisory committee votes are advice; FDA makes the final decision. Sport status follows the WADA Prohibited List in force since January 1, 2026; athletes should confirm with their anti-doping organization. Checked October 5, 2026. Status of every compound.
The Russian label calls Selank a modified version of tuftsin, a small immune peptide, and says it eases anxiety through an “original” action on the brain, without naming a target. In rats it changed the activity of dozens of nerve-signaling genes, which its authors link to GABA, the brain’s main calming signal. In human blood samples it slowed enzymes that break down enkephalins, the body’s own opioid-like peptides.
AnimalMainly from cell and animal studies; not shown in people.
Its actual target is unknown, as is how much reaches the brain from nose drops in people and whether the rat and lab findings explain the anti-anxiety effects reported in small Russian trials.
Russian 0.15% drops
2 drops per nostril 3× daily for 14 days. That is roughly 300 mcg per dose, estimated from the 0.15% strength; the label gives drops only.
250–500 mcg per dose, 1–3× daily, intranasal or by injection.
2 weeks on, 2 off, shown over 26 weeks
The ways Selank is most often run, each tagged with where it comes from.
Russian registration (0.15% nasal drops) for anxiety. The label says to repeat only after a doctor’s review.
Spray made from research powder, not the registered drops. Guides vary; some go up to about 1,000 mcg a day split.
Under the skin. No label or trial basis for injecting Selank.
Label: drops into each nostril; clear a runny or blocked nose first. Community injections go under the skin of the belly or thigh, rotating spots.
The Russian label has no missed-dose rule. Skip it and take the next dose on schedule; don’t double up.
Users describe a subtle calm without sleepiness, lasting a few hours.
CommunityIn a Russian trial of 62 patients, anxiety relief matched the benzodiazepine medazepam, with added anti-fatigue effects.
TrialThe Russian label says Selank doesn’t cause dependence or tolerance.
LabelUnpleasant taste when drops reach the throat (label; frequency not given)
Harmless; no need to stop.
Allergic reactions, sometimes delayed (label; frequency not given)
Stop and get help for rash, swelling or trouble breathing.
Nasal irritation or dryness (community reports)
Lower the dose or take a break; stop if it persists.
Rash, face or throat swelling, wheezing or trouble breathing, even days after starting (the label notes delayed allergic reactions).
From its label, human studies and precautions based on how it works, most important first.
Only interactions stated on a product label or measured in a human study are listed.
Label: a product label rules it out, warns about it or lists the interaction. Trial: seen in human studies, or a group those studies left out. Precaution: follows from how it works or from a related drug, and hasn’t been tested. This isn’t a complete list: a pharmacist or doctor can check a specific medicine or condition.
The most common pairing: Selank for calm, Semax for focus. Both are Russian nasal peptides; never studied together.
3 key published human studies, with how many people took part. Animal studies aren’t listed here.
In anxiety disorders, adding Selank (40 patients) brought an earlier response on the HDRS and fewer phenazepam side effects than phenazepam alone (30).
Medvedev et al., Zh Nevrol Psikhiatr Im S S Korsakova 2015, PMID 26356395
In generalized anxiety and neurasthenia, Selank (30 patients) and medazepam (32) eased anxiety about equally; Selank also eased fatigue.
Zozulia et al., Zh Nevrol Psikhiatr Im S S Korsakova 2008, PMID 18454096
In phobic-anxiety and somatoform disorders, Selank had a clear anti-anxiety effect that lasted about a week after the last dose; no effect sizes in the abstract.
Medvedev et al., Zh Nevrol Psikhiatr Im S S Korsakova 2014, PMID 25176261
Selank’s human evidence is a few small Russian trials in anxiety disorders, with 60–70 people each, that compared it with or added it to benzodiazepines rather than placebo; the abstracts give few numbers. Its mechanism rests on rat and lab studies. Injection, long-term use and the purity of research vials are untested.
| Vial | Water | Common dose | Draw | Strength | Action |
|---|---|---|---|---|---|
| 5 mg | 2 mL | 300 mcg | 12 units (0.12 mL) | 2.5 mg/mL | |
| 10 mg | 3 mL | 300 mcg | 9 units (0.09 mL) | 3.333 mg/mL |
To match the label’s 1.5 mg/mL strength for nasal use: 5 mg in 3.3 mL, or 10 mg in 6.7 mL.
Syringe units for common doses at different water volumes. Select a cell to open it in the calculator.
| Dose | Water added | ||
|---|---|---|---|
| 1 mL | 2 mL | 3 mL | |
| 250 mcg | |||
| 300 mcg | |||
| 400 mcg | |||
| 500 mcg | |||
U-100 insulin syringe: 100 units is 1 mL. Draws over 100 units show in mL. Faded values are under 2 units, which is hard to measure. Check that your vial holds the larger volumes.
Every compound side by side: the half-life chart and the storage chart.
A seven-amino-acid peptide built from the immune peptide tuftsin plus a stabilizing Pro-Gly-Pro tail.
The Russian label calls Selank a modified version of tuftsin, a small immune peptide, and says it eases anxiety through an “original” action on the brain, without naming a target. In rats it changed the activity of dozens of nerve-signaling genes, which its authors link to GABA, the brain’s main calming signal. In human blood samples it slowed enzymes that break down enkephalins, the body’s own opioid-like peptides. Its actual target is unknown, as is how much reaches the brain from nose drops in people and whether the rat and lab findings explain the anti-anxiety effects reported in small Russian trials.
Approved in Russia as 0.15% nasal drops for anxiety; not approved in the US. Nomination withdrawn, so Selank acetate is no longer in FDA Category 2 (April 2026). Not on the July 2026 advisory committee agenda.
From the label (Russian 0.15% drops): 2 drops per nostril 3× daily for 14 days. That is roughly 300 mcg per dose, estimated from the 0.15% strength; the label gives drops only. From community reports, not established: 250–500 mcg per dose, 1–3× daily, intranasal or by injection. These are the amounts sources reference, not recommendations.
There’s no single right amount, because the water only sets the strength. With 2 mL of bacteriostatic water in a 5 mg vial, the strength is 2.5 mg/mL, so 300 mcg is 12 units on a U-100 insulin syringe. More water makes small doses easier to measure. The dose chart above shows other volumes.
Pregnancy or breastfeeding: Ruled out by the Russian label because no clinical studies were done. Children and teens under 18: Ruled out by the label; it was never studied in them. Allergy to Selank or parabens: Ruled out with allergy to any ingredient. The drops contain a paraben preservative (methyl parahydroxybenzoate), which the label says can cause allergic reactions, including delayed ones. The “Who should avoid it” section lists 1 more group and 2 interactions.
A few minutes, according to the prescribing information. Russian label, nasal drops: found in blood within 30 seconds, then levels fall over 5 to 5.5 minutes. No formal half-life is given.
Before mixing: Freezer (about −20 °C) for long-term storage; fridge for short periods. After mixing: Fridge (2–8 °C); use within about 4 weeks. This is common practice; no product label covers it.
No. Not named on the 2026 list. It is approved in Russia, so S0 (non-approved substances) does not apply.
Yes. The human studies section lists 3 published studies. The largest, from 2015, included 70 people. In anxiety disorders, adding Selank (40 patients) brought an earlier response on the HDRS and fewer phenazepam side effects than phenazepam alone (30).
For the protocol details
For how it works, who should avoid it and the limits of the evidence
Doses tagged Community come from public dosing guides and user reports, checked against at least two of them. Those sites aren’t named here because many of them sell peptides or earn commissions on them.